Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;48(7):1525-1538.
doi: 10.1007/s40618-025-02548-x. Epub 2025 Feb 19.

Artificial intelligence in the management of metabolic disorders: a comprehensive review

Affiliations
Review

Artificial intelligence in the management of metabolic disorders: a comprehensive review

Aamir Anwar et al. J Endocrinol Invest. 2025 Jul.

Abstract

This review explores the significant role of artificial intelligence (AI) in managing metabolic disorders like diabetes, obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), and thyroid dysfunction. AI applications in this context encompass early diagnosis, personalized treatment plans, risk assessment, prevention, and biomarker discovery for early and accurate disease management. This review also delves into techniques involving machine learning (ML), deep learning (DL), natural language processing (NLP), computer vision, and reinforcement learning associated with AI and their application in metabolic disorders. The following study also enlightens the challenges and ethical considerations associated with AI implementation, such as data privacy, model interpretability, and bias mitigation. We have reviewed various AI-based tools utilized for the diagnosis and management of metabolic disorders, such as Idx, Guardian Connect system, and DreaMed for diabetes. Further, the paper emphasizes the potential of AI to revolutionize the management of metabolic disorders through collaborations among clinicians and AI experts, the integration of AI into clinical practice, and the necessity for long-term validation studies. The references provided in the paper cover a range of studies related to AI, ML, personalized medicine, metabolic disorders, and diagnostic tools in healthcare, including research on disease diagnostics, personalized therapy, chronic disease management, and the application of AI in diabetes care and nutrition.

Keywords: Artificial intelligence; Deep learning; Machine learning; Metabolic disorders.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no potential conflicts of interest concerning this article’s research, authorship, and/or publication. Ethical approval: Not applicable. Consent to participate: Not applicable. Consent to publication: Not applicable.

References

    1. Bhai SF, Vissing J (2023) Diagnosis and management of metabolic myopathies. Muscle Nerve. https://doi.org/10.1002/mus.27840 - DOI - PubMed
    1. Natesan V (2022) Therapeutics in Metabolic Diseases. In: Advances in experimental medicine and biology. pp 255–273
    1. Song BG, Choi SC, Goh MJ et al (2023) Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma. JHEP Rep. https://doi.org/10.1016/j.jhepr.2023.100810 - DOI - PubMed - PMC
    1. Park JG (2023) Unraveling metabolic dysfunction-Associated fatty liver disease: refining sub-phenotypes for resolving its heterogeneity. Gut Liver 17:489–490. https://doi.org/10.5009/gnl230222 - DOI - PubMed - PMC
    1. Marschner RA, Roginski AC, Ribeiro RT et al (2023) Uncovering actions of type 3 deiodinase in the metabolic dysfunction-Associated fatty liver Disease (MAFLD). https://doi.org/10.3390/cells12071022 . Cells 12:

LinkOut - more resources